Study Links Viagra Use to Increased Risk for Skin Cancer

An April 2014 study by the Journal of the American Medical Association has indicated that use of the drug sildenafil, also known as Viagra, may lead to an increased risk for melanoma.

Melanoma is a dangerous form of skin cancer.  The study found that men using Viagra were 84 percent more likely to develop melanoma than men that did not use Viagra.  A study of over 25,000 patients found that when comparing patients that had not previously used Viagra to the patients that had, the patients using Viagra were twice as likely to develop melanoma.

Viagra is a medication that is prescribed to treat erectile dysfunction.  It was first approved by the Food and Drug Administration in 1998 and since then it has been prescribed to over 20 million men.  The popular “blue pill” has been aggressively marketed to consumers through television and print advertising since its inception and was even featured as a primary sponsor for a NASCAR racing team for several seasons during the 2000’s.

Since Viagra was approved and made available for use in the United States, several other drugs used to combat erectile dysfunction have also been approved by the Food and Drug Administration.  Drugs Cialis and Levitra are other popular medications prescribed to treat erectile dysfunction.

The study that links Viagra use to the potential risk for skin cancer did not link Cialis or Levitra to the increased risk for melanoma as the study began prior to those drugs being on the market.  The study indicated the need for additional research on the link between drugs used to treat erectile dysfunction and their link to melanoma.

DeMayo Law Offices, L.L.P. are currently investigating claims involving the link between drugs used to treat erectile dysfunction and skin cancer.  Victims injured by dangerous drugs may be entitled to compensation for pain & suffering, medical bills and other damages.

If you or a loved one has been diagnosed with melanoma after using Viagra or another erectile dysfunction medication, please contact DeMayo Law Offices, L.L.P. for a Free Case Evaluation.  DeMayo Law Offices, L.L.P. can be reached Toll Free at 1-877-333-1000 or via email at [email protected]

Office Locations

With North Carolina office locations in Charlotte, Hickory, Monroe and in Columbia, South Carolina, DeMayo Law Offices have been serving the state since 1992. You can contact us 24/7 and if you are unable to come to us - we will come to you.


FREE CASE EVALAUATION

Provide the below information and we will contact you.

  • This field is for validation purposes and should be left unchanged.
Phone icon
Call Us 24/7
Location icon
Convenient
Locations
home icon
We Come
To You

Please do not include any confidential or sensitive information in this form. This form sends information by non-encrypted email which is not secure. Submitting this form does not create an attorney-client relationship.




Member of the Multi-Million Dollar Advocates Forum Member of the Million Dollar Advocates Forum Top 100 Trial Lawyers North Carolina Advocates for Justice
AV Preeminent Client Champion The Law Offices of Michael A. DeMayo is a BBB Accredited Business Rated by Super Lawyers

Membership in the Million Dollar Advocates Forum is limited to attorneys who have won million and multi-million dollar verdicts and settlements. Criteria for membership in Million Dollar Advocates can be found by clicking here. DeMayo Law Offices, L.L.P. does not represent that similar results will be achieved in your case. Each case is different and must be evaluated separately.

The National Trial Lawyers is a national organization composed of the Top 100 Trial Lawyers from each state. Membership is obtained through special invitation and is extended only to those attorneys who exemplify superior qualifications, leadership, reputation, influence, stature, and profile as trial lawyers, both civil plaintiff and criminal defense. More information can be found at the National Trial Lawyers web site by clicking here. DeMayo Law Offices, L.L.P. does not represent that similar results will be achieved in your case. Each case is different and must be evaluated separately.